<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02391194</url>
  </required_header>
  <id_info>
    <org_study_id>AVB620-C-001</org_study_id>
    <nct_id>NCT02391194</nct_id>
  </id_info>
  <brief_title>Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery</brief_title>
  <official_title>A Phase 1 Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avelas Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avelas Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-label, dose escalation study in women with primary, non-recurrent&#xD;
      breast cancer undergoing surgery. AVB-620 will be administered prior to surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will examine the safety and tolerability of AVB-620 administered as an IV infusion&#xD;
      to women with primary, non-recurrent breast cancer undergoing surgery. The study will also&#xD;
      characterize the pharmacokinetics of AVB-620 in this subject population and determine the&#xD;
      dose of AVB-620 needed to generate a fluorescence signal in tumor and lymph node tissue to&#xD;
      enable fluorescence recordings and image analysis with an imaging system. The study will also&#xD;
      evaluate the effect of timing of AVB-620 administration, relative to surgery, on fluorescence&#xD;
      characteristics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of AVB-620 as assessed by the incidence of adverse events and abnormal laboratory values</measure>
    <time_frame>30 days</time_frame>
    <description>The incidence, nature and severity of adverse events and abnormal laboratory values will be collected and analyzed in the evaluation of the safety of AVB-620.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize the pharmacokinetic profile of AVB-620</measure>
    <time_frame>8 days</time_frame>
    <description>The pharmacokinetics (PK) of AVB-620 will be characterized by collecting and reviewing individual subject plasma concentrations and primary parameters, including clearance, Cmax, Cmin, and distribution.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>AVB-620</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive a single dose of AVB-620 as an intravenous infusion before the surgical procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AVB-620</intervention_name>
    <arm_group_label>AVB-620</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ductal carcinoma in situ (DCIS) or Stage I-III, primary invasive carcinoma of the&#xD;
             breast&#xD;
&#xD;
          -  Primary surgical treatment is planned to be a mastectomy or lumpectomy. Sentinel lymph&#xD;
             node (LN) biopsy or axillary LN dissection (ALND) is planned as part of the subject's&#xD;
             therapy.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2&#xD;
&#xD;
          -  Adequate renal function&#xD;
&#xD;
          -  Lab values (hematology and chemistry) within institution's normal laboratory limits&#xD;
&#xD;
          -  Willing to remain on-site for approximately 24 hours after administration of AVB-620&#xD;
             or, if required, stay overnight after the surgical procedure&#xD;
&#xD;
          -  If the subject received neoadjuvant therapy, residual tumor is present (to be&#xD;
             determined by the primary surgeon)&#xD;
&#xD;
          -  If the subject received prior anthracycline therapy, the left ventricular ejection&#xD;
             fraction (LVEF) must be within institution's normal limits&#xD;
&#xD;
          -  Subject has the ability to understand and the willingness to sign a written informed&#xD;
             consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recurrent ipsilateral breast cancer&#xD;
&#xD;
          -  Prior neoadjuvant chemotherapy or biologic therapy for current clinically or&#xD;
             biopsy-proven node positive breast cancer within 4 weeks before the planned surgery.&#xD;
&#xD;
          -  Open surgery in the ipsilateral breast within 1 year of AVB-620 administration&#xD;
&#xD;
          -  History of radiation therapy to ipsilateral breast&#xD;
&#xD;
          -  Abnormal cardiac rhythm not controlled with medication, history of stroke, coronary&#xD;
             events, and/or heart failure within 1 year of AVB-620 administration&#xD;
&#xD;
          -  Diagnosis of autoimmune disorders&#xD;
&#xD;
          -  History of drug-related anaphylactic reactions or allergic reactions; subjects with an&#xD;
             active diagnosis of uncontrolled airway hyperactivity, uncontrolled asthma, or asthma&#xD;
             requiring oral corticosteroids will be excluded&#xD;
&#xD;
          -  History of renal disease or current evidence of renal disease&#xD;
&#xD;
          -  Current diagnosis of any other active or clinically significant non-breast cancer&#xD;
&#xD;
          -  Systemic investigational drug of any kind within 6 weeks of AVB-620 administration&#xD;
&#xD;
          -  Pregnant or breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Moores UC San Diego Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Hospitals and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>February 20, 2015</study_first_submitted>
  <study_first_submitted_qc>March 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2015</study_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AVB-620</keyword>
  <keyword>stage I</keyword>
  <keyword>newly diagnosed</keyword>
  <keyword>breast cancer</keyword>
  <keyword>stage II</keyword>
  <keyword>stage III</keyword>
  <keyword>ductal carcinoma in situ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>January 26, 2018</submitted>
    <returned>September 21, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

